Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

The renowned global comprehensive kidney care provider has a market capitalization of $15.17 billion. The company projects 20.2% growth over the next five years and expects to maintain its strong performance going forward. DaVita’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 2.4%.

Image Source: Zacks Investment Research

Growth Drivers for DVA Stock

Strength in Integrated Kidney Care: DaVita’s IKC platform remains a prime growth driver as the company continues to expand its value-based care capabilities. After achieving its first full year of profitability in 2025, IKC maintained strong momentum in the first quarter of 2026, delivering year-over-year improvements across all three CMS Comprehensive Kidney Care Contracting (CKCC) performance metrics, including gross savings rates, quality scores and high-performing status. IKC generated the highest aggregate savings among all CKCC participants, underscoring the effectiveness of its data-driven care model. The company is reinforcing this strategy through its recently announced 2030 Community Care commitments, which include reducing avoidable hospitalizations, expanding transplant access and educating more patients on kidney care options.

Operational Execution Boosts Outlook: DaVita delivered a solid first-quarter performance, prompting management to raise its 2026 adjusted operating income and adjusted EPS guidance. The strong performance was driven by balanced execution across treatment volumes, revenue per treatment and patient care costs. Better-than-expected mortality trends, improving labor productivity and patient transfers related to Fresenius clinic closures supported an increase in the company’s treatment growth outlook from flat to 25 to 50 basis points for 2026. Management expects continued labor efficiencies to support margins. Disciplined capital allocation remains a positive, with DaVita repurchasing 5 million shares through the first quarter and thereafter. The combination of improving operating trends and disciplined cost management strengthens management’s confidence in delivering stronger earnings growth.

Technology Investments and Innovation: DaVita continues to invest in technology and clinical innovation to strengthen its competitive position and improve patient outcomes. During the first quarter, management highlighted investments in digital infrastructure and AI-enabled operational tools, including ScheduleHub, which dynamically optimizes staffing and patient scheduling to improve caregiver efficiency and operational productivity. These investments build on the company’s proprietary data infrastructure and are expected to support both clinical excellence and long-term operating leverage. Beyond technology, DaVita’s initiatives include the MODEL quality improvement program, the MEMOIRS prospective cohort study and strategic investment in Elara Caring to expand home-based support for patients with end-stage kidney disease. Management believes these initiatives are intended to improve patient outcomes, support caregivers, reduce hospitalizations and strengthen DaVita's value-based care platform.

Downsides of DVA Stock

Reimbursement Uncertainty and Dependence on Commercial Payers: Despite a strong first quarter, reimbursement uncertainty continues to represent a meaningful headwind. Management indicated that Affordable Care Act marketplace enrollment trends are tracking slightly better than expected but maintained its estimated $40 million headwind for 2026 due to limited visibility into enrollment, affordability and future patient mix. DaVita heavily depends on commercial insurers, which account for a large share of dialysis profits despite representing a small portion of total patients. Any deterioration in commercial payer mix, increased migration toward government-sponsored plans, or lower reimbursement from Medicare Advantage could pressure revenue per treatment and profitability. The anticipated decline in commercial mix over the course of 2026 further supports management’s expectation for only modest revenue-per-treatment growth.

Regulatory and Competitive Pressures: DaVita operates in one of the healthcare industry's most heavily regulated environments, exposing the company to reimbursement changes, compliance requirements and government oversight. Evolving Medicare and Medicaid policies, healthcare transparency regulations and increased enforcement activity could result in higher compliance costs or operational disruptions. Competition remains intense across the kidney care landscape. Besides competing with Fresenius Medical Care and other dialysis providers for patients, acquisitions and physician relationships, DaVita is facing growing competition from companies investing in value-based kidney care, transplant services and innovative treatment technologies. As the industry continues to evolve, maintaining market share while adapting to regulatory and competitive dynamics will remain critical to sustain long-term growth.

Macroeconomic Pressures and Investment Spending: DaVita continues to face external cost pressures stemming from inflation, labor market tightness, supply chain challenges and macroeconomic uncertainty. Although productivity improvements helped lower patient care costs during the first quarter, management acknowledged that general and administrative expenses increased as the company continued investing in technology and digital capabilities. While these investments are expected to generate long-term operational benefits, management noted that it remains early in the AI deployment cycle and that financial returns will materialize gradually. Combined with wage inflation, higher operating costs and economic uncertainty, these elevated investments could limit near-term margin expansion.

Estimate Trend

DaVita is witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for earnings per share has remained unchanged at $15.07.

The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $3.53 billion, indicating a 4.5% uptick from the year-ago quarter’s reported number. The consensus mark for earnings is pegged at $4.01 per share, implying 35.9% year-over-year growth.

Stocks to Consider

Some better-ranked stocks from the broader medical space are West Pharmaceutical WST, McKesson MCK and Cardinal Health CAH, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.

McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research